PLG and intracranial hemorrhage: In addition, the same hemostatic safety advantage over plasminogen activator has been reported with the use of direct fibrinolytic (mainly plasmin and microplasmin).36, 37 At the 4 μg/g BW dose, SCE5‐HtPlg did not consume plasma fibrinogen and was not associated with any brain hemorrhage or gastrointestinal effect at 24 hours after administration in healthy animals.